← Evidence library

BIB_174

Weber JS et al. Adjuvant Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma (CheckMate-238). NEJM 2017;377(19):1824–1835. PMID 28891423. RFS HR 0.65 favouring nivo. Companion adjuvant trial. [Tasks: 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

18

Identifiers

PMID:28891423

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_174/findings.md (research corpus). This page is a short context summary — not individualised medical advice.